

Dopamine D2 receptor antagonist - Pipeline Insight, 2022

<https://marketpublishers.com/r/D9AEF96F4F9BEN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: D9AEF96F4F9BEN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Dopamine D2 receptor antagonists - Pipeline Insight, 2022" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Dopamine D2 receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Dopamine D2 receptor antagonists Understanding

Dopamine D2 receptor antagonists: Overview

DRD2 encodes the D2 subtype of the dopamine receptor that inhibits adenylyl cyclase activity. Alternative splicing of this G protein-coupled receptor results in two transcript variants encoding different isoforms. DRD2 plays a major role in the neural circuitry that mediates behavioral control, an ability that is essential for adaptive responding and is compromised in a variety of common neuropsychiatric disorders.

Function – Dopamine receptors are G protein–coupled receptors involved in the regulation of motor activity and several neurological disorders such as schizophrenia,

bipolar disorder, Parkinson's disease (PD), Alzheimer's disease, and attention-deficit/hyperactivity disorder. Dopamine is a monoamine catecholamine neurotransmitter belonging to the 7 transmembrane G protein-coupled receptors (GPCRs), which play an important role in the regulation of not only motor functions but also non-motor functions such as motivation, cognition, emotion, and neuroendocrine secretion.

Dopamine D2 receptor antagonists- Dopamine (DA) D2 receptor antagonists have been linked to elevated levels of nicotine dependence in smokers with schizophrenia. Because activation of D2 receptors mediates motivation for nicotine, potent D2 antagonists would diminish nicotine's ability to stimulate reward processing-a mechanism that may drive compensatory increases in smoking.

Dopamine D2 receptor antagonists Emerging Drugs Chapters

This segment of the Dopamine D2 receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Dopamine D2 receptor antagonists Emerging Drugs

Pridopidine: Prilenia Therapeutics

Pridopidine is an oral drug currently in development for the treatment of Huntington's disease and ALS. It is administered in a small easy-to-swallow capsule twice a day. Pridopidine is being evaluated in Phase III stage of development for the treatment of patients with Huntington's disease.

FKF 02SC: Fabre-Kramer Pharmaceuticals

FKF 02SC is a potent dopamine D2 receptor antagonist being developed by Fabre-Kramer Pharmaceuticals. The drug is currently in Phase II stage of development for the treatment of patients with Schizophrenia.

Further product details are provided in the report.....

Dopamine D2 receptor antagonists: Therapeutic Assessment

This segment of the report provides insights about the different Dopamine D2 receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Dopamine D2 receptor antagonists

There are approx. 10+ key companies which are developing the Dopamine D2 receptor antagonists. The companies which have their Dopamine D2 receptor antagonists drug candidates in the most advanced stage, i.e. Phase III include, Prilenia Therapeutics

Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Dopamine D2 receptor antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Dopamine D2 receptor antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dopamine D2 receptor antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dopamine D2 receptor antagonists drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Dopamine D2 receptor antagonists R&D. The therapies under development are focused on novel approaches for Dopamine D2 receptor antagonists.

Dopamine D2 receptor antagonists Report Insights

Dopamine D2 receptor antagonists Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Dopamine D2 receptor antagonists Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Dopamine D2 receptor antagonists drugs?

How many Dopamine D2 receptor antagonists drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Dopamine D2 receptor antagonists?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Dopamine D2 receptor antagonists therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Dopamine D2 receptor antagonists and their status?

What are the key designations that have been granted to the emerging drugs?

Contents

Introduction

Executive Summary

Dopamine D2 receptor antagonists: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Dopamine D2 receptor antagonists – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Dopamine D2 receptor antagonists companies' collaborations, Licensing, Acquisition
-Deal Value Trends

Dopamine D2 receptor antagonists Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Pridopidine: Prilenia Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

FKF 02SC: Fabre-Kramer Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

MRTX-1133: Mirati Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Dopamine D2 receptor antagonists Key Companies

Dopamine D2 receptor antagonists Key Products

Dopamine D2 receptor antagonists- Unmet Needs

Dopamine D2 receptor antagonists- Market Drivers and Barriers

Dopamine D2 receptor antagonists- Future Perspectives and Conclusion

Dopamine D2 receptor antagonists Analyst Views

Dopamine D2 receptor antagonists Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Dopamine D2 receptor antagonists

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Dopamine D2 receptor antagonists

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Dopamine D2 receptor antagonist - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/D9AEF96F4F9BEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D9AEF96F4F9BEN.html>